OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Globoh Ig. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
OBI is eligible to receive up to US$ 200 million in total milestone payments and tiered double-digit royalties on net sales. TAIPEI, Taiwan, Feb. 22, 2022 /PRNewswire/ -- OBI Pharma, Inc.
/PRNewswire/ -- OBI Pharma, Inc. (OBI), a Taiwan biopharma company (TPEx: 4174), and Odeon Therapeutics (Odeon), a China biopharma company, have entered into...
/PRNewswire/ -- OBI Pharma, Inc. (OBI), a Taiwan biopharma company (TPEx: 4174), and Odeon Therapeutics (Odeon), a China biopharma company, have entered into...